Clinical Trials
64 trialsNeo-CD
Second Affiliated Hospital, School of Medicine, Zhejiang University
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Fudan University
TRIPLE-PATH
Jinling Hospital, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune Inc
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
FEMUS
Fudan University
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Chinese PLA General Hospital
ROSETTE
Shanghai Zhongshan Hospital
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Corbus Pharmaceuticals Inc.
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Changhai Hospital
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Jinzhou Medical University
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Jinling Hospital, China
SPARC
Ruijin Hospital
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
University Health Network, Toronto
mRCAT-III
Sir Run Run Shaw Hospital
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Corbus Pharmaceuticals Inc.
CRIT
Sixth Affiliated Hospital, Sun Yat-sen University
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Fudan University
CCGLC-001
Tongji Hospital
HiR+X
First Affiliated Hospital of Ningbo University
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
Fudan University
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Peking University Third Hospital
TORCH-E
Fudan University
mRCAT
Sir Run Run Shaw Hospital
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
TORCH-R
Fudan University
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Zhejiang Cancer Hospital
Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
Energenx Medical LTD.
CCGLC-008
Tongji Hospital